BAROnova

Currently, over half of the adult population in the U.S. is overweight or obese. Of these patients, more than 6 million are 100 pounds or more overweight with an additional 15 million more nearly there. Those suffering from this obesity epidemic are at an increased risk to a range of diseases, including: Type II diabetes, heart disease, stroke, high blood pressure, high cholesterol, certain cancers, and other disorders.

Recent studies have indicated that obesity can reduce lifespan by an average of 3 years in adults and 20 years in children. Despite this fact, there are no effective non-invasive therapies available and often patients struggling with obesity must resort to the complicated, and potentially fatal, major bowel surgery involved in gastric bypass or gastric reduction. In fact, recent data have indicated that even in the lowest risk groups, obesity surgery has an average 1-year mortality rate of nearly 5%.

BAROnova's patent pending technology has the potential to revolutionize the treatment of obesity.